Physician profile
Derek Huffman
NPI 1861060600
$8,241.65
in general payments reported to CMS, 2019-2025
40 companies · $2,057 in 2025
The $2,057 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $174 · 2023: $3,493 · 2024: $2,519 · 2025: $2,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,893 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,893.16 |
| Education | $174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $874.34 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $796.79 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $775.24 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $625.84 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $524.91 | 2022-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $509.93 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $507.27 | 2022-2025 | |
| Glaxosmithkline, LLC. | $495.93 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $301.90 | 2022-2025 | Nexletol |
| Insulet Corporation | $247.38 | 2023-2025 | Omnipod |
| Amgen INC. | $241.97 | 2023-2024 | Repatha, Otezla, Evenity |
| Exact Sciences Corporation | $211.10 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.34 | 2024 | Xifaxan, Trulance |
| Sumitomo Pharma America, INC. | $167.77 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.68 | 2023-2025 | Jardiance, Synjardy, Spiriva |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $138.44 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $130.23 | 2024-2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $128.43 | 2023 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $117.49 | 2023-2025 | Auvelity |
| Impel Pharmaceuticals INC. | $112.55 | 2022-2023 | Trudhesa |
| Otsuka America Pharmaceutical, INC. | $104.40 | 2025 | Rexulti |
| Sanofi Pasteur INC. | $94.48 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $92.07 | 2023-2024 | Linzess |
| Merck Sharp & Dohme LLC | $85.92 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Vanda Pharmaceuticals INC. | $81.89 | 2024-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $62.08 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $61.39 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $61.01 | 2023 | |
| Mylan Specialty L.P. | $58.99 | 2023-2024 | Yupelri |
| Corcept Therapeutics | $57.72 | 2023 | Korlym |
| Dexcom, INC. | $40.63 | 2023-2025 | Dexcom G6 Transmitter |
| Viatris Specialty LLC | $38.50 | 2025 | Yupelri |
| Cequr Corporation | $31.03 | 2024-2025 | Cequr Simplicity |
| Idorsia Pharmaceuticals US INC | $22.86 | 2023 | Quviviq |
| Phadia US INC. | $20.50 | 2025 | Immunocap |
| Ironshore Pharmaceuticals INC. | $20.03 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.40 | 2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $16.81 | 2024 | Xarelto |
| Currax Pharmaceuticals LLC | $16.72 | 2025 | Contrave |
| Organon LLC | $16.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Huffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.